Keywords: otc, zantac, outsells, centra, sb, brands, sales
OTC Zantac Outsells Centra, SB Brands
Article | 07 August 1995
Sales of Glaxo Wellcome's over-the-counter H2 antagonist Zantac 75 (ranitidine) have overtaken those of its competitors, SmithKline Beecham's Tagamet 100 (cimetidine) and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
